CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), today
announced that John P. Butler, President and Chief Executive Officer,
will be presenting at the following investor conferences:
The 15th Annual Morgan Stanley Global Healthcare Conference
on Monday, September 11, 2017 at 9:55 a.m. Eastern Time. The
conference is being held at the Grand Hyatt New York.
The 19th Annual Rodman & Renshaw Global Investment
Conference on Tuesday, September 12, 2017 at 8:45 a.m. Eastern Time.
The conference is being held at the Lotte New York Palace Hotel.
The Cantor Fitzgerald 2017 Global Healthcare Conference on Tuesday,
September 26, 2017 at 2:50 p.m. Eastern Time. The conference is being
held at the InterContinental New York Barclay Hotel.
A live audio webcast of the presentations will be available on the
company's website at http://ir.akebia.com/events.cfm.
Archived presentations will be available for 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. Akebia's lead product candidate, vadadustat, is an oral,
investigational therapy in development for the treatment of anemia
related to chronic kidney disease in both non-dialysis and dialysis
patients. Akebia's global Phase 3 program for vadadustat, which includes
the PRO2TECT studies for non-dialysis patients with anemia
secondary to chronic kidney disease and the INNO2VATE studies
for dialysis-dependent patients, is currently ongoing. In addition, the
Company has initiated the Phase 2 FO2RWARD study of
vadadustat in dialysis-dependent chronic kidney disease patients who are
hyporesponsive to erythropoiesis-stimulating agents (ESAs), and expects
to commence the Phase 3 TRILO2GY study to further evaluate a
three-times-weekly dosing regimen for vadadustat. For more information,
please visit our website at www.akebia.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005498/en/
Theresa McNeely, 617-844-6113
Communications and Investor Relations
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media